Republic Services Inc. Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Republic Services Inc. Common Stock trades at $227 (market cap $67.34B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: Republic Services Inc. Common Stock is the larger of the two by market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals.
| RSG | RVMD | |
|---|---|---|
Market Cap | $67.34B | $40.39B |
Volume | 955,255 | 2,941,009 |
Sector | Industrials | Health |
52-Week High | $232.27 | $221.15 |
52-Week Low | $197.73 | $49.56 |
Enterprise Value | $81.53B | $37.09B |
Dividend Yield | 1.22% | — |
Typical Hold Time | — | 2 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →